Anti-HuD E [62] Product

Affinity purified biotinylated antibody directed against HuD E, the mutant HuD neoantigen expressed in SCLC, melanoma and neuroblastoma.

Tumour Antigens Blog Post

[…] the result of malignant mutations or the expression of viral elements (1,2). They include: > Neoantigens, produced as a direct consequence of genetic alteration caused by tumour DNA mutations and […]

RMA-S.Trh4 cells Product

This cell line provides a model to help to understand T-cell recognition through Trh4 expression. ER-resident ceramide synthase Trh4 is a prototypic example of a neo-antigen selectively presented by cells through various pathways. RMA-S lymphoma cells are TAP-deficient on account of an incomplete TAP2 chain, whereas RMA cells have their TAP chain intact.

P815.Trh4 cells Product

This cell line provides a model to help to understand T-cell recognition through Trh4 expression.

RMA.Trh4 cells Product

This cell line over-expresses endogenous Trh4 and provides a key tool to help understand presentation of Trh4 to antigen recognition though other pathways.

RMA.Trh4 Db KO cells Product

This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Db gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db.

RMA.Trh4 Kb KO cells Product

This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Kb gene.